LAFAYETTE, La., December 18, 2025 — Tides Medical, a leader in advanced biologic solutions, today announced that multiple Tides Medical skin substitute products have been included on the Centers for Medicare & Medicaid Services’ (CMS) Medicare Administrative Contractor (MAC) Status Quo / Discretionary list following finalized updates to Local Coverage Determinations (LCDs), effective January 1, 2026.

Consistent with CMS’s published Frequently Asked Questions (FAQs), products placed in the MAC Discretionary (status quo) category have not experienced a change in coverage policy or payment status. These products will continue to be reimbursed under existing Medicare statutory and regulatory criteria, provided claims meet all applicable coverage, coding, and billing requirements. Covered products will be reimbursed at a standardized rate of $127 per cm², as announced by CMS on October 31, 2025.

“We are pleased that several Tides Medical products are included in this category,” said Joe Spell, Chief Executive Officer of Tides Medical. “This classification maintains current payment policies and supports continued access to the advanced products clinicians rely on while additional clinical evidence is finalized.”

Tides Medical invested in clinical evidence well in advance of these policy updates and remains focused on completing and submitting finalized data that reinforces the company’s long-term commitment to outcomes, integrity, and patient care.

Tides Medical Products Included on CMS MAC Discretionary (Status Quo) List Products included in the status quo category and expected to continue being reimbursed under current Medicare rules include:

• Q4336 – Artacent C®, per sq cm
• Q4337 – Artacent Trident®, per sq cm
• Q4338 – Artacent Velos®, per sq cm
• Q4339 – Artacent Vericlen®, per sq cm
• Q4169 – Artacent Wound®, per sq cm
• Q4190 – Artacent AC®, per sq cm

“The inclusion of these products in the status quo category reflects our sustained investment in scientific research and clinical support,” Spell continued. “As coverage policies evolve, Tides remains committed to delivering high-quality, clinically supported solutions—along with the service and responsiveness our customers expect.”

As healthcare reimbursement continues to evolve, Tides Medical will remain focused on supporting clinicians, advocating for appropriate patient access, and delivering solutions designed to help providers deliver efficient, effective care.

About Tides Medical Tides Medical is a biotechnology company that manufactures and distributes advanced wound care therapies, including human skin substitutes and advanced tissue products. Tides works closely with providers, hospitals, and clinical staff to navigate the complex reimbursement landscape, helping ensure patients have access to the full range of treatment options they deserve. For more information, visit www.tidesmedical.com.